Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in the developed world. Currently, there are 4 available intravitreal anti-VEGF therapies (pagaptanib, bevacizumab, ranimizumab and aflibercept). Brolucizumab is a newly developed anti-VEGF molecule for neovascular AMD treatment. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of exudative (wet) AMD. In this paper we summarize the safety, visual and anatomic outcomes of brolucizumab in the treatment of neovascular AMD. The aim of the study was to evaluate the efficacy in visual function improvement of brolucizumab with aflibercept in neovascular age-related macular degeneration (AMD). Fourteen patients, aged > 50 years , with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye. Eligible participants were randomized 1:1 to intravitreal injections of brolucizumab (6mg/50 μl) or aflibercept (2mg/50 μl). Both groups received 3 monthly loading doses and were then treated every 8 weeks. Brolucizumab demonstrated non inferiority to aflibercept in BCVA change from baseline. We observed superiority in Pelli Robson contrast sensitivity chart tests and decrease of metamorphopsia (perceptual distortion where linear objects appear curved and discontinuous) with Amsler test. In brolucizumab group greater central subfield thickness reductions from baseline were observed with brolucizumab 6 mg versus aflibercept. Anatomic retinal fluid outcomes favored brolucizumab over aflibercept. Brolucizumab was superior to aflibercept in visual function like contrast sensitivity and decrease of metamorphopsia. Anatomic outcomes favored brolucizumab over aflibercept.